Freeman Technology Unveils a New Guide to Powder Behaviour
Freeman Technology, a global leader in powder characterisation, has published a new educational guide entitled ‘An Introduction to Powders’. Written in a straightforward, easy to understand style, the new booklet explains how and why powders behave the way they do, and how this affects powder processing and characterisation. It provides a valuable foundation for those with little prior knowledge of powders, as well as being a useful resource for anyone looking to expand their understanding of the factors relevant to product development and processing performance. The booklet is now available to download free of charge via the Freeman Technology website at www.freemantech.co.uk/index.php?id=415
Powders are ubiquitous throughout industry with applications ranging from food and cosmetics to pharmaceuticals and ceramics. Understanding powder behaviour is an essential precursor to efficient processing. The new booklet, authored by Tim Freeman, Managing Director of Freeman Technology, focusses on how the three components of a powder — the particles, surrounding air and any moisture present — interact to define powder behaviour, and provides answers to the most frequently encountered powder processing issues throughout industry.
In addition to detailing the mechanisms that define powder behaviour, the new guide explores the importance of powder flowability across a range of industrial processes. It explains the significance of operational conditions in the context of powder processing and highlights direct correlations between dynamic powder properties and process performance.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.